The CBRA is a knowledge center for burden of disease and risk assessment methodology. It applies these methods to study the health and economic impact of public and animal health threats.


In a new study published in the European Journal of Cancer, we assessed the burden of melanoma by melanoma stage in terms of disability-adjusted life years. We developed a melanoma disease model to predict the evolution of patients from diagnosis until death, and calculated years lived with disability (YLD) and years of life lost (YLL) for each American Joint Committee on Cancer stage. We showed that YLD generated by localised melanoma which will never metastasize were inferior to YLL resulting from stage IA melanomas.

Go to our publications section to find out more.